Those who turned 73 in 2025 have until April 1, 2026 to take their first RMD. Older adults who haven't taken their 2025 RMDs yet will likely face a tax penalty. It's possible to reduce the tax penalty ...

Project 2025, a conservative think tank’s blueprint to reshape the United States under a Republican president, recognized Greenland’s “rising potential” and encouraged America to “enhance economic ...

Tax season is approaching, and millions of Americans will soon turn their attention to tax brackets. Every year, the Internal Revenue Service announces new tax brackets, tiers of income that are taxed ...

Attribution researches the influence of climate change on local weather and impacts. We issues alerts in many instances when the Climate Shift Index identifies a notable extreme weather event around ...

Apple emerged as the global smartphone market leader in 2025, capturing a 20% market share with 10% year-over-year shipment growth – the highest among the top five brands, according to data released ...

While it would be presumptuous to base conclusions solely on the number of drugs the FDA approved in 2025, it is noteworthy that FDA nods of new treatments fell short of previous years, though a surge ...

Drug developers secured approvals for 46 new therapeutic agents from the FDA’s Center for Drug Evaluation and Research (CDER) in 2025. This cohort brings the 5-year average down a touch, to 48 new ...

The Morningstar US Large-Mid Cap Index rose 17.71% in 2025. The large-mid index tracks the performance of the top 90% of the US investable universe by market cap, and each year we screen from among ...

2025 was a big year for cybersecurity, with major cyberattacks, data breaches, threat groups reaching new notoriety levels, and, of course, zero-day vulnerabilities exploited in incidents. Some ...

It's been a great year for movies. Revisit the best of the best, already on Netflix, HBO Max, and more. 2025 has come to an end, and with it comes a lot of reflection, both in terms of how the world ...

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S. research enterprise has been scrambled by a series of political decisions ...